Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC
In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non –clear cell renal cell carcinoma (RCC).02/20/2019
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Israel Health | Kidney Cancer | Middle East Health | Renal Cell Carcinoma | Urology & Nephrology